Abstract 215P
Background
The prognostic impact of total metabolic tumor volume (TMTV) measured on pretreatment 18F-FDG PET/CT and its added value to molecular characteristics was investigated in patients with diffuse large B-cell lymphoma (DLBCL).
Methods
For 47 newly diagnosed patients with DLBCL treated with rituximab and CHOP/CHOP-like regimen, TMTV was computed using the 40% SUVmax thresholding method. Overexpression of BCL2, BCL6 and MYC was seen with the use of immunohistochemistry.
Results
Median follow-up was 14.1 months. Out of 47 patients, one patient died after 3 cycles of chemotherapy due to disease progression; the remaing 46 have completed 6 cycles of R-CHOP chemotherapy. Twenty-nine (61.7%) patients had a complete response (CR) to therapy. Using Spearman's correlation test, total metabolic tumor volume was positively and significantly correlated with tumor response, NCCN IPI and LDH levels. In the CR group mean TMTV was263.7 which is statistically lower than the mean TMTV in the non CR group that is 481.3 (p value – 0.006). For prediction of CR, the estimated optimal cutoff TMTV value was 215 cm3 with 0.83 sensitivity and 0.52 specificity done with the aid of receiver-operating characteristics (ROC) curve analysis. BCL2, BCL6 and MYC overexpression was seen in 35 (74.5%), 35 (74.5%) and 20 (42.6%) patients, respectively. Dual expression was seen in 5 (10.6%) and triple expression in 14 (29.8%) patients. It was found to be statistically insignificant with any of the clinical factors. In univariate analysis TMTV, LDH, response rate and NCCN IPI were found to be statistically significant in predicting progression-free survival, but in multivariate analysis none of the factors except response rate were shown to be independently predictive of progression-free survival.
Conclusions
In our study TMTV had an independent impact on response rate as well as on patient survival. Molecular analysis needs a study with long-term follow up with a large sample size to establish a significant relationship. TMTV with NCCN-IPI can be used in guiding treatment decisions, particularly in high-risk patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
140P - Lenvatinib + everolimus in mRCC that has progressed on immunotherapy: A real-world single center experience
Presenter: CHINNU JOMI
Session: Poster viewing 03
141P - Real-world study of cabozantinib treatment of advanced renal cell carcinoma in Taiwan
Presenter: Yu-Chieh Tsai
Session: Poster viewing 03
143P - Clinical outcomes of systemic therapy for hemodialysis patients with metastatic renal cell carcinoma
Presenter: Shun Iwasa
Session: Poster viewing 03
144P - Association between immune-related adverse events and survival in metastatic renal cell carcinoma treated with nivolumab plus ipilimumab
Presenter: Takanori Hayase
Session: Poster viewing 03
145P - Treatment outcomes and FGFR alterations in unresectable locally advanced or metastatic urothelial cancer in Taiwan
Presenter: Jian-Ri Li
Session: Poster viewing 03
146P - Comparison of the survival outcomes between primary and secondary muscle-invasive bladder cancer: A propensity score-matched Chinese cohort
Presenter: WAICHAN LOK
Session: Poster viewing 03
Resources:
Abstract
147P - Activity of single-agent PD-1/PD-L1 inhibitors in 1st-line (1L) “platinum-ineligible” patients (pts) with metastatic urothelial cancer (mUC) in real-life clinical practice
Presenter: Javier Molina Cerrillo
Session: Poster viewing 03
149P - A need for clear definitions and improved management for BCG-unresponsive tumors in Asia-Pacific
Presenter: Lui Shiong Lee
Session: Poster viewing 03
Resources:
Abstract